Lei Shao

Lei Shao


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2022 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
JLJing Liu
Jing Liu
DYDakai Yang
Dakai Yang
XWXiaojing Wang
Xiaojing Wang
PAPaul Tetteh Asare
Paul Tetteh Asare
QZQingwen Zhang
Qingwen Zhang
LSLei Shao
Lei Shao
The liver is directly connected to the intestines through the portal vein, which enables the gut microbiota and gut-derived products to influence liver health. There is accumulating evidence of decreased gut flora diversity and alcohol sensitivity in patients with various chronic liver diseases, including non-alcoholic/alcoholic liver disease, chronic hepatitis virus infection, primary sclerosing cholangitis and liver cirrhosis. Increased intestinal mucosal permeability and decline in barrier function were also found in these patients. Followed by bacteria translocation and endotoxin uptake, these will lead to systemic inflammation. Specific microbiota and microbiota-derived metabolites are altered in various chronic liver diseases studies, but the complex interaction between the gut microbiota and liver is missing. This review article discussed the bidirectional relationship between the gut and the liver, and explained the mechanisms of how the gut microbiota ecosystem alteration affects the pathogenesis of chronic liver diseases. We presented gut-microbiota targeted interventions that could be the new promising method to manage chronic liver diseases.

10 July 2019 in Food & Function
Verified
Journal Article
Closed access
PDF file
HZHui Zhu
Hui Zhu
YZYan Zhou
Yan Zhou
YQYan Qi
Yan Qi
RJRui Ji
Rui Ji
JZJunliang Zhang
Junliang Zhang
DCDaijie Chen
Daijie Chen
The aim of this study was to investigate the characteristics of a novel selenium-enriched Bifidobacterium longum DD98 (Se-B. longum DD98) supplement food and its repairing effects on the intestinal ecology of mammals. We assessed the growth, Se accumulation, and Se biotransformation of B. longum DD98 and its effects on antibiotic-induced intestinal dysbacteriosis in mice. The viable bacterial count at the end of fermentation was not significantly affected by the presence of Se. Bifidobacterium longum DD98 took up inorganic Se from the medium and biotransformed it into Se-containing proteins and selenoamino acids. The dominant Se species was selenomethionine (SeMet), which comprised 87% of the total Se in Se-B. longum DD98. Furthermore, Se-B. longum DD98 showed better regulation of the disrupted intestinal microbiota back to normal levels and repaired damaged colon tissues compared to the natural recovery and B. longum DD98 treatments. These findings suggest that B. longum DD98 efficiently biotransformed inorganic Se into more bioactive organic Se forms and may have therapeutic potential for the restoration of antibiotic-induced intestinal dysbacteriosis.

17 November 2022 in Frontiers in Microbiology
Verified
Journal Article
Open access
XWXiaojing Wang
Xiaojing Wang
JLJiaying Li
Jiaying Li
JSJiaqi Shang
Jiaqi Shang
JBJing Bai
Jing Bai
KWKai Wu
Kai Wu
LSLei Shao
Lei Shao
α-Glucosidase and α-amylase are the two main glycosidases that participate in the metabolism of carbohydrates. Inhibitors of these two enzymes are considered an important medical treatment for carbohydrate uptake disorders, such as diabetes and obesity. Microbes are an important source of constituents that have the potential to inhibit glycosidases and can be used as sources of new drugs and dietary supplements. For example, the α-glucosidase inhibitor acarbose, isolated from Actinoplanes sp., has played an important role in adequately controlling type 2 diabetes, but this class of marketed drugs has many drawbacks, such as poor compliance with treatment and expense. This demonstrates the need for new microorganism-derived resources, as well as novel classes of drugs with better compliance, socioeconomic benefits, and safety. This review introduces the literature on microbial sources of α-glucosidase and α-amylase inhibitors, with a focus on endophytes and marine microorganisms, over the most recent 5 years. This paper also reviews the application of glycosidase inhibitors as drugs and dietary supplements. These studies will contribute to the future development of new microorganism-derived glycosidase inhibitors.

23 December 2019 in The Journal of Antibiotics
Verified
Journal Article
Closed access
PDF file
ZYZhijun Yang
Zhijun Yang
KWKai Wu
Kai Wu
YXYixin Xu
Yixin Xu
XXXing Xia
Xing Xia
XWXuejun Wang
Xuejun Wang
LSLei Shao
Lei Shao

1 September 2020 in Fitoterapia
Verified
Journal Article
Closed access
ZYZhi-Jun Yang
Zhi-Jun Yang
YZYi-Fan Zhang
Yi-Fan Zhang
KWKai Wu
Kai Wu
YXYi-Xin Xu
Yi-Xin Xu
XMXiang-Guo Meng
Xiang-Guo Meng
LSLei Shao
Lei Shao

26 December 2022 in Pharmaceutical Fronts
Verified
Journal Article
Open access
PDF file
LXLei Xu
Lei Xu
YMYu-Cheng Meng
Yu-Cheng Meng
PGPeng Guo
Peng Guo
MLMing Li
Ming Li
LSLei Shao
Lei Shao
JHJunhai Huang
Junhai Huang
PIM kinase is consequently emerging as a promising target for cancer therapeutics and immunomodulation. PIM kinases are overexpressed in a variety of hematological malignancies and solid tumors, and their inhibition has become a strong therapeutic interest. Currently, some pan-PIM kinase inhibitors are being developed under different phases of clinical trials. Based on the different scaffold structures, they can be classified into various subclasses. The X-ray structure of the kinase complex outlines the rationale of hit compound confirmation in the early stage. Structure–activity relationships allow us to rationally explore chemical space and further optimize multiple physicochemical and biological properties. This review focuses on the discovery and development of small-molecule pan-PIM kinase inhibitors in the current research, and hopes to provide guidance for future exploration of the inhibitors.